# Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

> **NCT04813653** · PHASE1 · COMPLETED · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 3 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** cyclosporine in combination with carfilzomib and dexamethasone

## Key facts

- **NCT ID:** NCT04813653
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-18
- **Primary completion:** 2025-03-05
- **Final completion:** 2025-03-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04813653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04813653, "Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04813653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*